C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
Interventions that preserve β-cell function are effective at improving metabolic outcomes in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We have shown that improvements in HbA1c are directly proportional to the degree of C-peptide preservation, quantifying this relationship, and supporting the use of C-peptides as a surrogate endpoint in clinical trials.
Interventions that preserve β-cell function are effective at improving metabolic outcomes
in new-onset type 1 diabetes, confirming their potential as adjuncts to insulin. We
have shown that improvements in HbA1c are directly proportional to the degree of C-peptide
preservation, quantifying this relationship, and supporting the use of C-peptides
as a surrogate endpoint in clinical trials.
